Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2024-03-27 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
$500,000 Convertible Loan Facility 2 pages 184.7KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 28th March 2024 from InhaleRx Ltd regarding entering into a $500,000 Convertible Loan Facility with Peak Asset Management. It details the terms of the loan facility, including interest rate, drawdowns, term, conversion terms, and fees. The content focuses on financing activity and capital structure changes, with no financial statements or quarterly/yearly results presented. The document length is 2985 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a report publication announcement or a regulatory filing of a different nature. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2024-03-27 English
Annual Report to shareholders 43 pages 784.4KB
Annual Report Classification · 100% confidence The document is titled 'Annual Report – 31 December 2023' and contains detailed sections typical of an annual report, including a Chairman's letter, Directors' report, financial results, business model, principal activities, and corporate governance information. It covers the full financial year ended 31 December 2023 and includes substantive financial data such as losses, revenue, and operational review. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-27 English
Corporate Governance Statement and Appendix 4G 18 pages 336.9KB
Governance Information Classification · 100% confidence The document is titled 'Corporate Governance Statement' and extensively discusses the company's governance framework, board responsibilities, management roles, board committees, policies, diversity and inclusion, risk management, and compliance with ASX Corporate Governance Council Principles and Recommendations. It includes detailed disclosures about governance practices, board composition, and policies, which are typical contents of a governance report. There is no indication that this is an announcement of a report or a brief summary; the document is substantive and detailed. It does not contain financial statements or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a proxy statement or voting results announcement. The focus on governance practices and policies aligns with the definition of Governance Information (CGR). Therefore, the document should be classified as Governance Information (CGR).
2024-03-27 English
Appendix 4G 12 pages 395.7KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It includes detailed disclosures about corporate governance practices, compliance with ASX Corporate Governance Council recommendations, and references to the company's Corporate Governance Statement. The document is not the corporate governance statement itself but a key to disclosures related to it. It is a regulatory filing required by the ASX to accompany the annual report, focusing on governance disclosures rather than financial results or management changes. The document is lengthy (15,000 characters) and contains substantive governance information, not just an announcement or certification. Therefore, it fits best under Governance Information (CGR).
2024-03-27 English
Proposed issue of securities - IRX 7 pages 25.8KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX announcement format used for the proposed issue of securities such as placements, convertible loans, and options. It details the terms, number, pricing, and conditions of the proposed securities issuance by Inhalerx Limited. The document is focused on capital raising activities and changes to the company's capital structure. It is not a full financial report, earnings release, or management discussion. It is not a regulatory certification or a report publication announcement. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (10,968 characters) and detailed content support this classification with high confidence.
2024-03-27 English
Shareholder Town Hall Webinar Slides 18 pages 7.4MB
Investor Presentation Classification · 100% confidence The document is titled as an ASX Announcement and contains presentation slides for a shareholder town hall webinar dated 20 March 2024. It includes detailed information about the company's products, market opportunities, regulatory pathways, and clinical trial updates. The content is structured as a presentation with slides, including charts, market data, and corporate updates. There is no indication that this is a full financial report, audit report, or earnings release. It is not a transcript of a call but rather a prepared presentation for investors and shareholders. The document length is substantial (15,000 characters), and it is clearly a presentation rather than a brief announcement or a report publication notice. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-03-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.